The influence of modifiable cardiovascular risk factors on cognition, functioning, and inflammatory markers in first-episode psychosis: Results from a 2-year follow-up study. (October 2022)

• Record Type: Journal Article
• Authors: Pujol, Nuria; Bergé, Daniel; Mané, Anna; Bioque, Miquel; Mezquida, Gisela; Amoretti, Silvia; Baeza, Inmaculada; González-Pinto, Ana; Lobo, Antonio; Cuesta, Manuel J.; Ribeiro, Maria; Sánchez-Tomico, Georgina; Pérez-Solà, V.; Verdolini, Norma; Vieta, Eduard; Parellada, Mara; Roldán, Alexandra; Bernardo, Miquel
• Is Part Of: Psychiatry research. Volume 316(2022)
• Publication Date: 2022-10
• Subjects: First-episode psychosis -- Cognition -- Cardiovascular risk factors -- Lymphocyte; Psychiatry -- Periodicals; Psychiatry -- periodicals; Psychiatrie -- Périodiques; 616.89
• DOI: 10.1016/j.psychres.2022.114760
• Languages: English
• ISSNs: 0165-1781

Abstract

Highlights: First Episode Psychosis patients with two or more cardiovascular risk factors showed a slower performance on the TMT-A test. First Episode Psychosis patients with two or more cardiovascular risk factors showed higher lymphocyte levels. No longitudinal changes were observed in cognitive nor white blood cell markers at 2-year follow-up. Our findings suggest the importance of targeting both cardiovascular risk factors and cognitive deficits in first-episode psychosis. Compared with First Episode Psychosis patients with zero or one cardiovascular risk factors. Abstract: To explore the influence of cardiovascular risk factors (CVRFs) on cognitive symptoms, functional impairment, and systemic inflammatory markers in first-episode psychosis (FEP) patients at baseline and 2-year follow-up. Method: In a sample of 70 FEP patients and 85 age- and sex-matched healthy controls, we assessed nine modifiable CVRFs. All participants were classified into two subgroups according to their CVRF profile: lower (0–1 CVRFs) or higher (≥2 CVRFs). The following outcomes were measured at baseline and 2-year follow-up: cognition; functional outcomes; and white blood cell (WBC) subtype. Adjusted general linear models were conducted to study the effect of diagnosis and CVRF profile on cognition, functioning, WBC, and longitudinal changes in these variables. At baseline, FEP patients with a higher CVRF profile showed a significantly slower performance on the TMT-A test for psychomotor speed and higher lymphocyte levels than patients with a lower CVRF profile. No longitudinal changes were observed in primary outcomes at 2-year follow-up. Among FEP patients with a higher CVRF profile, slower psychomotor speed performance did not correlate with increased lymphocyte levels. Our findings suggest that the cognitive effects of CVRFs manifest early in the course of psychosis, thus highlighting the importance of targeting both CVRFs and cognitive deficits in FEP.